Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPS804 in Adults With Hypophosphatasia
NCT01406977Phase 2Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Jul 2011
- Primary completion
- Sep 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of setrusumab in hypophosphatasia (HPP), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoints: Number of patients experiencing adverse events or serious adverse events at 141 days and Change from baseline in primary serological bone biomarkers at 141 days. Started Jul 2011; status: completed.
02
Drugs
setrusumab
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on NCT01406977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01406977.